BJC Reports

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.

BJC Reports

Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, Daud AI

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.

BJC Reports

Zoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, Chaorong Wu, Clinton Wu, Laura Huppert, Lauren S. Levine, Paula Sison, Katy K. Tsai, Melissa Chow, Jee Hye Kang, Jimmy Hwang, James C. Lee, Ariel Oglesby, Jessica Venegas, Ben J. Brintz, Aik Choon Tan, Mark S. Anderson, Michael D. Rosenblum, Arabella Young, Adil I. Daud